About Careers MedBlog Contact us

High Cost Making It Difficult for Canadians to Access Prescription Medicines

by Kathy Jones on September 19, 2013 at 10:37 PM
Font : A-A+

 High Cost Making It Difficult for Canadians to Access Prescription Medicines

A new study published in the Canadian Medical Association Journal reveals that high costs of drugs is making it difficult for people to procure prescription medicines outside hospitals.

Canada lacks a national pharmacare program, with drug costs borne by patients and a mix of private and publicly funded drug plans. Most insurance plans require copayments by patients, which can present a barrier to accessing needed drugs. Although provincial governments cover most or all drug costs for seniors and people on social assistance, the "working poor" do not have the same benefits, which can result in high rates of noncompliance and failure of patients to have their prescriptions filled.


"Patient-borne expenses for prescription drugs are an important issue and can have a negative impact on treatment access and outcomes," writes Dr. Braden Manns, University of Calgary, with coauthors. "Without better drug coverage systems, Canadians do not have universal health coverage."

Canada's patchwork system has many players who influence patient-related drug expenses, including federal and provincial-territorial governments, insurers and physicians. Physicians, for example, are often unaware of the difference in costs between two drugs with similar efficacy; they may prescribe a more expensive drug without recognizing the financial burden it may impose on a patient.

The authors recommend several solutions to these barriers including creating a national drug agency, changing the way Canada regulates patented drug prices, differential copayments for medications based on ability to pay or clinical value of a drug, and educating physicians on drug costs.

"A national drug agency would be well positioned to implement a universal drug program, where all Canadians would have access to some type of drug coverage," although the authors acknowledge barriers to a national plan.

Source: Eurekalert


Recommended Reading

Latest Drug News

 India's First Urinary Incontinence Drug Launched
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
 New Ray of Hope for Atrial Fibrillation Patients With Kidney Disease
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Anti-viral Drug Bulevirtide Helps Treat Chronic Hepatitis D
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Antiviral Drug Paxlovid Linked to Lower Risk of Hospital Admission
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Price Cap Move Will Place Eli Lilly Strongly in Insulin Market
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

High Cost Making It Difficult for Canadians to Access Prescription Medicines Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests